DR 10627
Alternative Names: DR-10627Latest Information Update: 28 Feb 2026
At a glance
- Originator Zhejiang Doer Biologics
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
- No development reported Diabetes mellitus; Metabolic disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for phase-I development in Diabetes-mellitus in China (Parenteral)
- 18 Feb 2026 Phase-I clinical trials in Obesity in China (Parenteral) (Zhejiang Doer Biologics pipeline, February 2026)
- 18 Feb 2026 Zhejiang Doer Biologics completes a phase I trial in Obesity and Diabetes mellitus in China (Zhejiang Doer Biologics pipeline, February 2026)